Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder
Early Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT06414889
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT06412198
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT06408168
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
Recruiting
- Conditions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06409052
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 400
- Registration Number
- NCT06409065
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06401603
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06397027
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06389721
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT06383572
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
Recruiting
- Conditions
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2000
- Registration Number
- NCT06377527
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath